Protect your dog from parasites, inside and out
Protect your dog from parasites, inside and out
Search
Osteoarthritis in dogs: Protecting your pet from pain
Osteoarthritis in dogs: Protecting your pet from pain
How do you know if your cattle have parasites?
How do you know if your cattle have parasites?
A versatile solution for PCV2 and PRRS protection
A versatile solution for PCV2 and PRRS protection
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot
• Boehringer Ingelheim Animal Health Canada Inc. launches a unique vaccine combination that protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv) in one shot
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Protecting Animals and Humans
Everything we do is about improving the health and well-being of humans and animals.
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Toronto nurse from Princess Margaret Hospital named as the 2019 Oncology Nurse of the Year by the Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (CANO/ACIO)
Toronto nurse from Princess Margaret Hospital named as the 2019 Oncology Nurse of the Year by the Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (CANO/ACIO)
Does your PRRS vaccine have sufficient “horsepower?”
Does your PRRS vaccine have sufficient “horsepower?”
The Hidden Cost of Parasites in Cattle
The Hidden Cost of Parasites in Cattle
Vaccine protection against different PRRS virus strains
Vaccine protection against different PRRS virus strains
Effective management practices for parasite control in cattle
Effective management practices for parasite control in cattle
Treatment options for parasite control in cattle
Treatment options for parasite control in cattle
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Strategies for overcoming resistance in parasites
Strategies for overcoming resistance in parasites
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Thank you for submitting your report
multistep form
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study
Simple and straight to the source: tips for ileitis control
Simple and straight to the source: tips for ileitis control